Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: A Turkish Oncology Group study

Basit Öğe Kaydı
dc.authorid0000-0003-2184-634X
dc.contributor.authorHızal, Mutlu
dc.contributor.authorBilgin, Burak
dc.contributor.authorPaksoy, Nail
dc.contributor.authorKılıçkap, Sadettin
dc.contributor.authorAtcı, Muhammed Mustafa
dc.contributor.authorKahraman, Seda
dc.contributor.authorKeskinkılıç, Merve
dc.contributor.authorBilgetekin, İrem
dc.contributor.authorAyhan, Murat
dc.contributor.authorTural, Deniz
dc.contributor.authorEren, Önder
dc.contributor.authorAkkoç Mustafayev, Fatma Nihan
dc.contributor.authorYaman, Şebnem
dc.contributor.authorTatlı, Ali Murat
dc.contributor.authorBayram, Ertuğrul
dc.contributor.authorKutlu, Yasin
dc.contributor.authorErtürk, İsmail
dc.contributor.authorÖzcan, Erkan
dc.contributor.authorGülmez, Ahmet
dc.contributor.authorKorkmaz, Mustafa
dc.contributor.authorAkagündüz, Baran
dc.contributor.authorErdem, Dilek
dc.contributor.authorAkın Telli, Tuğba
dc.contributor.authorAksoy, Asude
dc.contributor.authorÜskent, Necdet
dc.contributor.authorİriağaç, Yakup
dc.contributor.authorKöse Baytemür, Naziyet
dc.contributor.authorAydın, Dinçer
dc.contributor.authorSakalar, Teoman
dc.contributor.authorArak, Haci
dc.contributor.authorSelçukbiricik, Fatih
dc.contributor.authorErgün, Yakup
dc.contributor.authorKorkmaz, Taner
dc.contributor.authorAk, Naziye
dc.contributor.authorÜnal, Çağlar
dc.contributor.authorAkdeniz, Nadiye
dc.contributor.authorÖzgün, Mehmet Alpaslan
dc.contributor.authorÖksüzoğlu, Berna
dc.contributor.authorYalçın, Bülent
dc.contributor.authorÖztop, İlhan
dc.contributor.authorAlgın, Efnan
dc.contributor.authorSakin, Abdullah
dc.contributor.authorAydıner, Adnan
dc.contributor.authorYumuk, Perran Fulden
dc.contributor.authorŞendur, Mehmet Ali Nahit
dc.date.accessioned2022-07-29T07:34:59Z
dc.date.available2022-07-29T07:34:59Z
dc.date.issued2022
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractAims: In this multicenter study, the authors aimed to determine the real-life efficacy and safety of first-line alectinib. Materials & methods: This retrospective trial included advanced-stage, ALK-positive non-small-cell lung cancer patients who were treated with first-line alectinib in terms of ALK-tyrosine kinase inhibitors, regardless of previous chemotherapy. The co-primary end points were progression-free survival both for all patients and for the treatment-naive population. The secondary end points were overall response rate, overall survival, rate of CNS progression and safety. Results & conclusion: A total of 274 patients (n = 177 for treatment-naive patients) were enrolled in the study. The median progression-free survival was 26 and 28.8 months for all patients and the treatment-naive group, respectively. The overall response rate, CNS progression rate and 1-year overall survival ratio were 77.9, 12.4 and 77%. Alectinib is a highly effective therapy with a favorable safety profile.
dc.identifier.citationHızal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S. ... Şendur, M. A. N. (2022). Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: A Turkish Oncology Group study. Future Oncology, 18(23), 2573-2582. https://doi.org/10.2217/fon-2022-0083
dc.identifier.doi10.2217/fon-2022-0083
dc.identifier.endpage2582
dc.identifier.issn1479-6694
dc.identifier.issn1744-8301
dc.identifier.issue23
dc.identifier.pmid35734870
dc.identifier.scopus2-s2.0-85134156033
dc.identifier.scopusqualityQ2
dc.identifier.startpage2573
dc.identifier.urihttps://doi.org/10.2217/fon-2022-0083
dc.identifier.urihttps://hdl.handle.net/20.500.12511/9620
dc.identifier.volume18
dc.identifier.wos000814515100001en_US
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorKutlu, Yasin
dc.language.isoen
dc.publisherFuture Medicine Ltd.
dc.relation.ispartofFuture Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAlectinib
dc.subjectALK
dc.subjectFirst-Line
dc.subjectNon-Small-Cell Lung Cancer
dc.subjectReal-World
dc.titleReal-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: A Turkish Oncology Group study
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu